Market closedNon-fractional

Evolus/EOLS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Evolus

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Ticker

EOLS

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Newport Beach, United States

Employees

279

Evolus Metrics

BasicAdvanced
$688M
Market cap
-
P/E ratio
-$1.04
EPS
1.48
Beta
-
Dividend rate
$688M
1.48
3.211
2.803
680.475
686.721
-2.10%
-10.69%
-472.61%
2.876
36.88
-13.78
-24.352
40.45%
-18.13%
55.63%
-35.88%

What the Analysts think about Evolus

Analyst Ratings

Majority rating from 8 analysts.
Buy

Evolus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-22.09% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$59M
-2.63%
Net income
-$13M
11.02%
Profit margin
-22.09%
14.04%

Evolus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.29%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.16
-$0.12
-$0.09
-
Expected
-$0.19
-$0.17
-$0.07
-$0.11
-$0.03
Surprise
-2.26%
-8.05%
79.10%
-14.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Evolus stock?

Evolus (EOLS) has a market cap of $688M as of July 05, 2024.

What is the P/E ratio for Evolus stock?

The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of July 05, 2024.

Does Evolus stock pay dividends?

No, Evolus (EOLS) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Evolus dividend payment date?

Evolus (EOLS) stock does not pay dividends to its shareholders.

What is the beta indicator for Evolus?

Evolus (EOLS) has a beta rating of 1.48. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Evolus stock

Buy or sell Evolus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing